Pfizer Licenses Akcea’s AKCEA-ANGPTL3-LRx
By Michelle Liu
Pharma Deals Review: Vol 2019 Issue 10 (Table of Contents)
Published: 11 Oct-2019
DOI: 10.3833/pdr.v2019.i10.2460 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Highlighting its commitment to cardiovascular and metabolic diseases, Pfizer has agreed to license AKCEA-ANGPTL3-LRx from Akcea Therapeutics, a majority-owned affiliate of Ionis Pharmaceuticals...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS